NCT01390441: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) |
|
|
| Terminated | 1 | 100 | RoW | MK-8808, MabThera® (rituximab), Rituxan®, Rituximab, Methotrexate, Trexall®, Rheumatrex®, Rituxan® (rituximab), Methylprednisolone, Acetaminophen, Paracetamol, Loratadine, Claritin® | Merck Sharp & Dohme LLC | Rheumatoid Arthritis | 04/14 | 04/14 | | |
